News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Urinary Bladder → cancer profile · × Clear filters
Benefit from perioperative enfortumab vedotin–pembrolizumab in cisplatin-eligible MIBC
In the randomized phase 3 KEYNOTE-B15/EV-304 trial (n=808), perioperative enfortumab vedotin plus pembrolizumab outperformed standard neoadjuvant cisplatin-gemcitabine in cisplatin-eligible muscle-invasive bladder cancer. At 2 years, event-free survival was 79.4% versus 66.2% (HR 0.53; 95% CI 0.41-0.70; P<0.001), overall survival was 86.9% versus 81.3% (HR 0.65; 95% CI 0.48-0.89; P=0.006), and pat…
Systemic induction therapy and the expanding frontier of bladder preservation in MIBC
A review published in Nature Reviews Clinical Oncology examines two recent phase II trials, INDIBLADE and SURE-02, which explore whether systemic induction therapy can enable bladder preservation in patients with muscle-invasive bladder cancer (MIBC). Traditionally, radical cystectomy or radiotherapy has been the standard of care for MIBC, but increasingly effective systemic regimens are raising t…